Preparation and application of cyperus esculentus oil phosphatidylserine fat emulsion preparation containing vitamin AD
By dissolving vitamin AD in sarco oil and preparing sarco oil with phosphoesterylserine wrapping material, the problems of insoluble and low bioavailability of vitamin AD in water are solved, and further High stability and absorption efficiency, suitable for preventing and treating vitamin A and D deficiency.
Patent Information
- Application Number
- CN202410992799.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-15
AI Technical Summary
The existing vitamin AD fatty milk preparations are insoluble in water, are intolerant of heat, light and acid, and are prone to oxidation, resulting in low bioavailability. The use of soybean oil in traditional preparations has risks of sensitization and bioavailability problems.
Dissolve vitamin AD in sarcoa oil, use phosphoesterylserine as packaging material to prepare sarcoa oil phosphoesterylserine fat emulsion, and form a stable emulsion through emulsification and homogenization to avoid contact with water to improve stability and absorption. .
It improves the bioavailability and stability of vitamin AD, solves the problem of insoluble in water, and provides a safe and easy-to-absorbing formulation form suitable for the prevention and treatment of vitamin A and D deficiency.
Smart Images

Figure BDA0004959321160000031 
Figure BDA0004959321160000032 
Figure BDA0004959321160000041
Abstract
Description
Technical Field
[0001] The invention belongs to the fields of food, health products and medicine, and relates to phosphatidylserine fat emulsion and cyperus oleifera oil AD, in particular to a preparation of cyperus oleifera oil phosphatidylserine fat emulsion containing vitamin AD. Background Art
[0002] The cyperus rotundus originated in the Nile River Basin in Africa. It was the staple food of primitive African humans 2 million years ago. The cyperus rotundus is drought-resistant, flood-resistant, and salt-alkali-resistant, and is suitable for planting in sandy land. The oil content of the cyperus rotundus is 20% to 32%, and the oil yield per mu is 4 times that of soybeans. It is a new type of high-oleic acid healthy edible oil. The World Health Organization (WHO) believes that cyperus rotundus oil will perfectly replace "trans fat" oil products. The oleic acid content of cyperus rotundus oil is high, accounting for 75%-77% of the fatty acid composition, and the content of linoleic acid and linolenic acid is low, accounting for about 9.7%-9.9% and 0.15%-0.45% of the fatty acid composition. The linolenic acid and linoleic acid content of cyperus rotundus oil is rich, and the ratio is close to that in breast milk, which is most easily absorbed by the human body; cyperus rotundus is rich in oleic acid, calcium, potassium, zinc, selenium and other mineral nutrients necessary for the development of the brain, bones, and muscles of infants and young children. African babies use cyperus rotundus milk instead of breast milk after weaning.
[0003] Jatropha oil is non-allergenic, has high content of unsaturated fatty acids and minerals, contains linoleic acid and linolenic acid at a ratio close to that in breast milk, and has safety properties, making it an ideal carrier of fat-soluble vitamins AD.
[0004] Vitamin A and D supplementation can prevent and treat diseases caused by vitamin A and D deficiency, such as rickets, osteomalacia, and increased susceptibility to respiratory and digestive tract infections caused by subclinical vitamin A deficiency. 【1】 , night blindness, dry eyes, dry keratosis and osteoporosis in the elderly. It can also be used for children who need to supplement vitamin AD.
[0005] Fat emulsion vitamin AD is insoluble in water, intolerant to heat, light, and acid, unstable, easily oxidized, and has low oral bioavailability. For example, the presence of five conjugated double bonds and hydroxyl or ester groups in vitamin A alcohol and its ester derivatives makes it chemically active, and it is very easy to undergo oxidation, dehydration, and polymerization reactions under the action of light, oxygen, etc., which leads to changes in its structure, resulting in reduced retention rate and bioavailability.
[0006] Traditional preparations dissolve A and D in soybean oil to prepare them into oil solutions, drop pills, soft capsules and other preparations. The ratio of essential fatty acids in soybean oil is not optimal, and soybean oil has the risk of oil being pressed from genetically modified soybeans. Patients who are allergic to soybeans and their products cannot take such products, and the problem of low bioavailability is not solved.
[0007] Phosphatidylserine is an active substance in the cell membrane. It can help the cell wall maintain flexibility and enhance the efficiency of neurotransmitters that transmit brain signals, helping the brain to operate efficiently and stimulating the brain's activation state. It is an important nutrient element for maintaining normal brain memory, reaction and healthy emotions. Fat emulsion preparations are thermodynamically unstable preparations. Adding phosphatidylserine can enhance the fluidity of fat emulsion particles and improve the stability of the preparation.
[0008] Phosphatidylserine cyperus oil fat emulsion solves the water solubility problem of fat-soluble vitamin AD, increases stability and improves bioavailability. At the same time, it improves the therapeutic efficacy of vitamin AD. The preparation can be used to prevent and treat vitamin A and D deficiency. Such as rickets, osteomalacia, increased susceptibility to respiratory and digestive tract infections caused by subclinical vitamin A deficiency, night blindness, dry eyes, dry and keratinized skin, and osteoporosis in the elderly. Children who need vitamin AD supplementation. Summary of the invention
[0009] The object of the present invention is to provide a vitamin AD fat emulsion preparation, wherein vitamin AD is dissolved in cyperus oleiferus oil, and phosphatidylserine is used as a packaging material to prepare a drug-loaded cyperus oleiferus oil fat emulsion. The problem that fat-soluble vitamin AD is insoluble in water is solved. Since the cyperus oleiferus oil loaded with vitamin AD is wrapped in fat emulsion droplets, contact with an external aqueous solution is completely isolated, so degradation can be avoided and stability is improved. The cyperus oleiferus oil fat emulsion containing vitamin AD can increase the absorption of vitamin AD and improve its bioavailability.
[0010] The purpose of the present invention can be achieved through the following technical solutions:
[0011] A cyperus oleifera oil phosphatidylserine fat emulsion preparation containing vitamin AD, wherein the weight composition of each component in every 1000 ml is as follows:
[0012]
[0013] Preferably, in every 1000ml, the weight composition of each component is as follows:
[0014]
[0015] More preferably, in every 1000ml, the weight composition of each component is as follows:
[0016]
[0017] Most preferably, see Examples.
[0018] The fat emulsion of the present invention comprises cyperus oleifera oil which is refined and purified and meets the pharmaceutical standards, wherein the content of unsaturated fatty acids shall not be less than 80%, the ratio of oleic acid to linoleic acid is (5-7):1, and the peroxide value is ≤1mmol·L -1 , methoxyaniline value ≤ 2mg·ml -1 , lysophosphatidylcholine ≤1.2mg / mL.
[0019] In the fat emulsion preparation of the present invention, the phosphatidylserine is one or more of soybean phosphatidylserine, sunflower seed phosphatidylserine, cotton seed phosphatidylserine, peanut seed phosphatidylserine, pine nut phosphatidylserine, egg yolk phosphatidylserine, and synthetic phosphatidylserine, or may be a mixed phospholipid of several different phosphatidylserines in any proportion.
[0020] In the fat emulsion preparation of the present invention, the lecithin emulsifier is one or more of soybean lecithin, egg yolk lecithin, soybean lecithin, egg yolk lecithin, and synthetic lecithin, or a mixture of several different lecithins in any proportion.
[0021] In the fat emulsion preparation of the present invention, the oleic acid co-emulsifier is oleic acid or sodium oleate.
[0022] The fat emulsion preparation of the present invention can be an oral liquid, a lyophilized powder, a lyophilized powder capsule, a lyophilized powder granule, or a syrup.
[0023] The fat emulsion of the present invention can be used to prevent and treat vitamin A and D deficiency, such as rickets, osteomalacia, increased susceptibility to respiratory and digestive tract infections caused by subclinical vitamin A deficiency, night blindness, dry eyes, dry keratinized skin, and senile bone loss, and children who need vitamin AD supplementation.
[0024] The present invention provides a method for preparing vitamin AD cyperus oleifera oil fat emulsion, comprising the following steps:
[0025] Add cyperus oleiferus oil to the reactor, heat it to the oil temperature of 30-70℃ under nitrogen protection, add the prescribed amount of vitamin AD, phosphatidylserine, lecithin emulsifier, and oleic acid emulsifier to the cyperus oleiferus oil, and completely dissolve the added substances under stirring; slowly add the cyperus oleiferus oil solution, stir it at high speed (3000r / min) with a shearing machine to about 700mL of pure water / injection water buffer solution, and continue stirring for 30min under nitrogen protection to obtain cyperus oleiferus oil phosphatidylserine fat emulsion colostrum containing vitamin AD. Homogenize the colostrum with a high-pressure homogenizer 2-4 times at a pressure of 100MPa, and control the particle size to be below 500nm. Dilute with water for injection, add flavoring agent, thickener (or diluent), pigment, preservative, fill and sterilize. The final product should be a uniform white milky solution without precipitation and stratification. After bottling, the product should be stored in a cool and dark environment.
[0026] If the particle size of the phosphatidylserine cyperus oleifera oil emulsion needs to be controlled during the above preparation process, a homogenizer, a micro jet pump and other equipment may be used for particle size control.
[0027] Furthermore, the cyperus oleifera oil is refined and purified and meets the pharmaceutical standards, wherein the unsaturated fatty acid content is not less than 80%, the ratio of oleic acid to linoleic acid is (5-7):1, and the peroxide value is ≤1mmol·L -1 , methoxyaniline value ≤ 2mg·ml -1 , lysophosphatidylcholine ≤1.2mg / mL.
[0028] Furthermore, the jatropha oil has the dual functions of an oil-soluble drug carrier and a medicinal and nutritional active ingredient such as polyunsaturated acids in the formula.
[0029] Furthermore, the phosphatidylserine is one or more of soybean phosphatidylserine, sunflower seed phosphatidylserine, cotton seed phosphatidylserine, peanut seed phosphatidylserine, pine nut phosphatidylserine, egg yolk phosphatidylserine, and synthetic phosphatidylserine, or it can be a mixed phospholipid of several different phosphatidylserines in any proportion.
[0030] Furthermore, the phosphatidylserine in the formula has the dual functions of an emulsifier and a neuroprotective and neurorestorative medicinal brain-boosting nutritional active ingredient.
[0031] Furthermore, the lecithin emulsifier is one or more of soybean lecithin, egg yolk lecithin, soybean lecithin, egg yolk lecithin, and synthetic lecithin, or a mixture of several different lecithins in any proportion.
[0032] Furthermore, the oleic acid emulsifier is oleic acid or sodium oleate.
[0033] Furthermore, the cyperus oleifera oil phosphatidylserine fat emulsion preparation of vitamin AD of the present invention can be an oral liquid, a freeze-dried powder, a freeze-dried powder capsule, a freeze-dried powder granule, or a syrup.
[0034] Furthermore, the preparation of the present invention can be used to prevent and treat vitamin A and D deficiency, such as rickets, osteomalacia, increased susceptibility to respiratory and digestive tract infections caused by subclinical vitamin A deficiency, night blindness, dry eyes, dry keratinized skin, and senile bone disease, and children who need vitamin AD supplementation.
[0035] Beneficial effects of the present invention:
[0036] 1. The present invention provides a cyperus oleifera oil fat emulsion injection containing AD, which has uniform emulsion particles, good stability, little change in drug content before and after sterilization, and is not easy to break the emulsion and aggregate when stored for a long time at room temperature.
[0037] 2. The phosphatidylserine in the formula can not only maintain the stability of fat emulsion particles and reduce demulsification before and after sterilization, but also nourish the brain nerves of the user. Most of the vitamin AD supplement users are infants, pregnant women, and the elderly. These people also have the need for brain health. Taking the present invention can meet the needs of patients at the same time.
[0038] 3. The pharmaceutical preparation excipients cyperus oleifera oil and phosphatidylserine used in the present invention are both safe health care products. Cyperus oleifera has a high oleic acid content, a reasonable ratio of omega-6 and omega-3, and rich mineral nutrients such as oleic acid, calcium, potassium, zinc, and selenium necessary for bone and muscle development, as well as phosphatidylserine that promotes the brain growth of infants and young children, which strengthen the nutritional and health care treatment synergistic effect of the preparation. DETAILED DESCRIPTION
[0039] The present invention is further described by examples, and the scope of the present invention is not limited to the following examples. Professionals in the field can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. The materials and test methods used in the experiments of the present invention are generally and / or specifically described. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible here. The examples only further illustrate the details of the present invention, rather than limiting the present invention. Since the clinical dosage of vitamin AD has been regulated by clinical guidelines, the content in the preparation remains basically unchanged. Therefore, the present invention only investigates and verifies the dosage of cyperus juncea oil and the dosage of phosphatidylserine. Part I: Dosage range of cyperus juncea oil
[0040] The present invention verifies the dosage range of cyperus oleifera oil. Under the process conditions of the present invention, any dosage of cyperus oleifera oil in the range of 5-20% by weight listed in the claims of the present invention can ensure that a stable phosphatidylserine fat emulsion containing vitamin AD of cyperus oleifera oil can be prepared.
[0041] Example 1: Formulation with low content of cyperus oleifera oil (5% by weight)
[0042] Ingredient name Feeding amount Vitamin A Palmitate 180mg <![CDATA[Vitamin D3]]> 1mg Phosphatidylserine 5g Lecithin (PC98%) 10g Oleic acid 3.4g glycerin 20g Cyperus oleifera oil 50g Vitamin E 5mg Water for injection Add to 1000ml
[0043] Take 50g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 1mg of vitamin D3, 5g of phosphatidylserine, 10g of lecithin (E98), 3.4g of oleic acid, and 5mg of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take another 600mL of water for injection, add 20g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, package, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0044] Example 2: Injection preparation with intermediate content of cyperus oleifera oil (10% cyperus oleifera oil content)
[0045] prescription:
[0046] Ingredient name Feeding amount Vitamin A Palmitate 180mg <![CDATA[Vitamin D3]]> 1mg Phosphatidylserine 10g Lecithin (PC98%) 12g Oleic acid 4g glycerin 22g Cyperus oleifera oil 100g Vitamin E 0.5g Water for injection Add to 1000ml
[0047] Take 100g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 11mg of vitamin D3, 10g of phosphatidylserine, 12g of lecithin (E98), 4g of oleic acid, and 0.5g of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take 600mL of water for injection, add 22g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, package, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0048] Example 3: Preparation with high content of cyperus oleifera oil (20% cyperus oleifera oil content)
[0049] prescription:
[0050] Ingredient name Feeding amount (g) Vitamin A Palmitate 180mg <![CDATA[Vitamin D3]]> 1mg Phosphatidylserine 10g Lecithin (PC98%) 12.8g Oleic acid 3.6g glycerin 20g Cyperus oleifera oil 200g Vitamin E 0.5g Water for injection Add to 1000ml
[0051] Take 200g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 1mg of vitamin D3, 10g of phosphatidylserine, 12.8g of lecithin (E98), 3.6g of oleic acid, and 0.5g of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take another 600mL of water for injection, add 20g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, subpackage, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0052] Part II: Dosage range of phosphatidylserine
[0053] The present invention verifies the dosage range of the listed phosphatidylserine. Under the premise of keeping the formula content of other prescriptions unchanged, any dosage of the listed phosphatidylserine within the weight content range of 1-3% under the process and conditions of the present invention can ensure that a stable phosphatidylserine fat emulsion preparation containing vitamin AD can be prepared.
[0054] Example 4: Preparation with minimum phosphatidylserine content (phosphatidylserine 1%)
[0055] prescription:
[0056] Ingredient name Feeding amount (g) Vitamin A Palmitate 180mg <![CDATA[Vitamin D3]]> 1mg Phosphatidylserine 10g Lecithin (PC98%) 12g Oleic acid 2.8g glycerin 19g Cyperus oleifera oil 50g Vitamin E 0.5g Water for injection Add to 1000ml
[0057] Take 50g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 1mg of vitamin D3, 10g of phosphatidylserine, 12g of lecithin (E98), 2.8g of oleic acid, and 0.5g of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take another 600mL of water for injection, add 19g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, subpackage, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0058] Example 5: Preparation with intermediate phosphatidylserine content (PS content 2%)
[0059] prescription:
[0060]
[0061]
[0062] Take 100g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 11mg of vitamin D3, 20g of phosphatidylserine, 12.5g of lecithin (E98), 2.6g of oleic acid, and 0.5g of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take 600mL of water for injection, add 21.4g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, package, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0063] Example 6: Preparation with the highest content of phosphatidylserine (PS content 3%)
[0064] prescription:
[0065] Ingredient name Feeding amount Vitamin A Palmitate 180mg <![CDATA[Vitamin D3]]> 1mg Phosphatidylserine 30g Lecithin (PC98%) 12.8g Oleic acid 3g glycerin 18g Cyperus oleifera oil 200g Vitamin E 0.5g Water for injection Add to 1000ml
[0066] Take 200g of refined cyperus oleifera oil, add 180mg of vitamin A palmitate, 31mg of vitamin D, 30g of phosphatidylserine, 12.8g of lecithin (E98), 3g of oleic acid, and 0.5g of vitamin E, add to 60℃ under nitrogen protection, and stir to dissolve for about 30min. Take another 600mL of water for injection, add 18g of glycerol, and prepare a buffer solution. Under nitrogen protection and stirring, add the cyperus oleifera oil solution containing vitamin AD to the glycerol aqueous solution to prepare colostrum, and adjust the total amount to 1000mL. Homogenize 2-3 times with a high-pressure homogenizer at a homogenization pressure of 100MPa until the particle size is less than 500nm, adjust the pH to 7.0-8.0, add flavoring, filter, subpackage, pass nitrogen, and seal. Sterilize at 121℃ for 15min, and package after passing the lamp inspection. Store in a cool place.
[0067] 5. Quality evaluation and stability study of phosphatidylserine fat emulsion of cyperus oleifera oil containing vitamin AD
[0068] 5.1. Quality evaluation of phosphatidylserine fat emulsion preparation containing vitamin AD from cyperus oleifera oil 5.1.1. Instruments, reagents and samples:
[0069] Emulsi Flex-C5 high pressure homogenizer (Avestin), Waters HPLC system, PSS NICOMP 380 particle size measurement system (Santa Barbara, Calif, USA.), 100DIOL 250*
[0070] 4.0 mm chromatography column (Merck LiChrosphe), UV-visible spectrophotometer (Backman); Labconco Stoppering Tray Dryer.
[0071] Oleic acid reference substance (Sigma, content 99%), lysophospholipid reference substance (Sigma, content 99%), palmitic acid for biochemistry (Sigma, content ≥99%), horseshoe crab reagent and water for horseshoe crab reagent inspection (produced by Zhanjiang Andus Biological Co., Ltd.), glycerol, vitamin E and other reagents were chromatographically pure, analytically pure or chemically pure.
[0072] The test samples were from examples of the present invention.
[0073] 5.1.2 Experimental methods:
[0074] The determination of pH value and emulsion size distribution refers to the Chinese Pharmacopoeia method. The emulsion size distribution is determined using the PSSNICOMP 380 particle size determination system. Take 0.5μl of sample and place it in a sample cup. Add blank medium to 10ml, shake well and count the percentage of particles >1 and >5μm. Among the total number of emulsions larger than 0.5μm, the number of emulsions larger than 1μm shall not exceed 3% and there shall be no emulsions larger than 5μm. In addition, according to the 2005 edition of the Chinese Pharmacopoeia method, HPLC is used to determine the content of free fatty acids and triglycerides in fat emulsion injection samples. At the same time, the content of lysophospholipids is determined by normal liquid chromatography, using diol column gradient elution and light scattering detector. The peroxide value is determined by sodium thiosulfate titration, and the oxyaniline content is determined by ultraviolet spectrophotometry.
[0075] 5.1.3 Experimental results:
[0076] The fat emulsion of the cyperus oleiferus oil PS fat emulsion preparation containing vitamin AD prepared by the present invention is a white emulsion. The size and distribution of the emulsion particles are measured using the PSS NICOMP 380 particle size measurement system. The particle size of the samples is all around 198-220nm, and the particle size distribution is also relatively moderate. The appearance, shape and particle size of the cyperus oleiferus oil PS fat emulsion containing vitamin AD all meet the requirements of the parenteral nutrition fat emulsion products specified in the pharmacopoeia.
[0077] The experiment also investigated the key quality parameters of the cyperus oleifera oil fat emulsion sample containing vitamin AD prepared in the example, such as pH value, large particle size particles, and vitamin AD content, and found that they all met the quality standards for fat emulsion products specified in the Pharmacopoeia, as shown in Table 1.
[0078] Since jatropha oil contains a large amount of unsaturated fatty acids, the quality of fat emulsion products can usually be measured by the peroxidation parameters generated by oxidation during the production process. The present invention also measured the important markers lysophospholipids, peroxide value and anisidine value of the samples prepared in the examples, and the results showed that the samples in the examples fully met the national pharmacopoeia standards (Table 2).
[0079] Table 1. Summary of quality test results of AD cyperus oil PS fat emulsion
[0080]
[0081]
[0082] Table 2. Determination results of lysophospholipids, peroxide value and anisidine content in cyperus oleifera oil PS fat emulsion containing vitamin AD
[0083]
[0084] 5.2 Stability of phosphatidylserine fat emulsion preparation containing cyperus oleifera oil and vitamin AD 5.2.1 Test method:
[0085] The cyperus oleifera oil PS fat emulsion samples containing vitamin AD were stored in the dark at 40°C for 1 month, and the pH value and free fatty acid concentration were determined according to the Chinese Pharmacopoeia method, and the appearance changes of the samples were recorded.
[0086] 5.2.2 Experimental Results
[0087] The cyperus oleifera oil PS fat emulsion sample containing vitamin AD prepared according to the embodiment was stored at 40°C in the dark for 1 month, and the pH value and free fatty acid concentration were measured. The results are shown in (Table 3). It can be seen that the pH and free fatty acid concentrations are affected by the changes in storage temperature and storage time. The results show that the pH value and free fatty acid concentration of the cyperus oleifera oil PS fat emulsion preparation containing vitamin AD after short-term storage at a higher temperature for 1 month are not much different from those at the initial stage of preparation. It still meets the quality standards of the national pharmacopoeia for fat emulsion products, indicating that the preparation sample meets the quality requirements for clinical use of drugs.
[0088] Table 3. Stability study of cyperus oleifera oil PS fat emulsion containing vitamin AD (40°C, 30 days)
[0089]
[0090] VI. Sensitization test of phosphatidylserine fat emulsion of cyperus oleifera oil containing vitamin AD
[0091] The active systemic allergy of guinea pigs can be used to evaluate the potential allergenicity of phosphatidylserine fat emulsion of cyperus oleifera oil containing vitamin AD in the systemic active allergy test of guinea pigs. Since it is difficult to observe allergic reactions after oral administration in a short period of time, the present invention uses an injection test to detect the possible allergenicity of the sample. 6.1. Experimental animals and samples:
[0092] Sixteen guinea pigs were randomly divided into two groups: experimental group (phosphatidylserine fat emulsion of cyperus oleifera oil containing vitamin AD, AD cyperus oleifera oil PS fat emulsion) control group, positive control group (albumin).
[0093] 6.2 Test methods:
[0094] Induction period: The test article (AD cyperus oil PS fat emulsion) and the positive control article were intravenously injected once a day on days 1, 3 and 5. The volume for each guinea pig was 1 mL.
[0095] Challenge Phase: Guinea pigs were challenged with the test article and positive control by IV injection on Days 19 and 26 (first 2 animals / sex / group and last 2 animals / sex / group, respectively). The challenge dose level was twice that used for induction.
[0096] In the study, animals were observed for mortality twice a day. The observation was made from immediately after the provocative administration to 3 hours after the administration and the observation was recorded. The time from the appearance to the disappearance of the allergic reaction symptoms also needed to be recorded. The body weight was measured 3 times during the pre-test period, once on the 1st day, 19th day and 26th day before administration, and once a week during the life period.
[0097] 6.3 Experimental results:
[0098] During the study, no unplanned deaths or treatment-related weight changes were found. No treatment-related clinical symptoms were found during the induction period. On days 19 and 26, no treatment-related clinical symptoms were found in the animals in the test group (AD zephyranthes oil PS fat emulsion) from the time of the provocative administration to 3 hours after administration. In the 8 animals in the positive control group (albumin), signs of allergic reactions were observed within 1 minute after IV provocative administration, including strong positive symptoms of allergic reactions: purpura, increased respiratory effort and / or ataxia, unsteady gait; and / or weak positive symptoms of allergic reactions: long hair, scratching the nose and / or fidgeting. The sensitization rate of animals in the positive control group was 100%, indicating that the test system worked under the conditions of this study.
[0099] 6.4 Discussion
[0100] The acute allergic reaction test showed that under the conditions of this study, the test product (AD cyperus oil PS fat emulsion) prepared by the present invention was administered to guinea pigs without any signs of sensitization, which proved that the preparation of the present invention has good safety.
[0101] VII. Bioavailability of Cyperus oleifera oil fat emulsion containing vitamin AD
[0102] 7.1 Experimental animals and groups:
[0103] Male Wistar rats, weighing 260-280g. This example is divided into 5 experimental groups: the dosage and administration route of each group are as follows: (1) AD vegetable oil preparation (control group): Vitamin A palmitate and vitamin D3 are dissolved in 100mL soybean oil, mixed evenly under nitrogen protection, and vitamin AD vegetable oil oral preparation is prepared; the dosage is 1ml (130μg / kg·d). (2) AD cyperus oil PS fat emulsion preparation group (experimental samples 1-5): oral emulsions 1-5 prepared according to Examples 1-5; the dosage according to the vitamin AD content is 1ml.
[0104] 7.2 Experimental methods:
[0105] Wistar rats were randomly divided into 6 groups, 6 rats in each group, and fasted for 12 hours before the experiment, but not water. Six groups of preparations were gavaged to the rats, and 0.5 mL of blood was collected from the orbital venous plexus at 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h and 12h after administration, and collected in heparinized test tubes. After being kept in a 37℃ water bath for 30min, the blood was centrifuged at low temperature for 10min (5000r / min), and the plasma was separated and the supernatant was taken and stored at 20℃ for determination of its drug concentration. Vitamin A and vitamin D are both fat-soluble drugs with low bioavailability. HPLC was used to detect the content of the two components in plasma.
[0106] 7.3 Experimental Results
[0107] Wistar rats were gavaged with AD soybean oil (control) and AD cyperus oil PS fat emulsion (test samples 1-5). The blood drug concentration-time curve was measured and calculated by "DAS" pharmacokinetic calculation. It can be seen that the pharmacokinetic parameters of the tested AD cyperus oil PS fat emulsion samples 1-5 are very different from those of the control group, and the bioavailability of all fat emulsion samples is significantly improved (Table 4). Although within the scope of the claims, the bioavailability is significantly improved. However, the bioavailability of samples 2, 3, and 5 is better.
[0108] 7.4 Discussion
[0109] Vitamin AD is all fat-soluble compound, and its bioavailability is all lower.Fat emulsion is the tiny droplet that vegetable oil is wrapped with phospholipid monolayer membrane, and vitamin AD is dissolved in cyperus juncea oil by the present invention, and then is wrapped with phosphatidylserine to form special fat emulsion.As mentioned above, cyperus juncea oil has good safety, is rich in unsaturated fatty acid, and its linoleic acid / linolenic acid ratio is close to breast milk, so it is the better choice of fat-soluble drug to take cyperus juncea oil as carrier.Fat emulsion is easy to absorb, can enter human blood efficiently.This experiment verifies this feature, and the cyperus juncea oil PS fat emulsion containing vitamin AD prepared according to the embodiment of the present invention is compared with AD oil solution, and its bioavailability improves 3-5 times.
[0110] Table 4. Bioavailability determination of cyperus oleifera oil PS fat emulsion containing vitamin AD
[0111] Experimental samples Tmax(h) Cmax(ug / mL) <![CDATA[AUC 0-24h (and h / mL)]]> AD oil solution (reference substance) 0.32 38.18 112.19 AD oil PS fat emulsion (sample 1) 0.29 80.87 373.12 AD oil PS fat emulsion (sample 2) 0.26 94.16 569.69 AD oil PS fat emulsion (sample 3) 0.27 92.23 528.28 AD oil PS fat emulsion (sample 4) 0.31 78.90 356.36 AD oil PS fat emulsion (sample 5) 0.28 91.26 519.78
[0112] In summary, the phosphatidylserine fat emulsion preparation of cyperus oleiferus oil containing vitamin AD of the present invention has the following advantages (see Table 5): 1) For the first time, cyperus oleiferus oil is used as a dissolving carrier for fat-soluble vitamins, which improves safety (cyperus oleiferus oil is non-allergenic, has a reasonable fatty acid ratio, and is free of genetically modified confusion). 2) The cyperus oleiferus oil fat emulsion preparation containing vitamin AD is prepared using phosphatidylserine as a packaging material, which solves the solubility of vitamin AD in water and also improves the stability and bioavailability of vitamin AD. 3) The compliance of clinical medication is improved, making it more convenient and safe for infants to use medication. 4) All natural excipients are used in the formula, which have good biocompatibility and compatibility. The excipients used not only act as emulsifiers, but also have nutritional and health-care effects. In short, the patent of the present invention is novel, creative, practical, and reproducible.
[0113] Table 5. Comparison of cyperus oleifera oil PS fat emulsion containing vitamin AD and existing vitamin AD dripping pills
[0114]
[0115] References
[0116] 【1】Child Health Branch of the Chinese Association of Preventive Medicine. Expert consensus on the clinical application of vitamin A and vitamin D in Chinese children[J]. Chinese Journal of Child Health, 2021, 29(01): 110-116.
Claims
1. A phosphatidylserine fat emulsion preparation containing vitamin AD, characterized in that: In 1000ml, the weight composition of each component is as follows:
2. The fat emulsion preparation according to claim 1, characterized in that The weight composition of each component in every 1000ml is as follows:
3. The fat emulsion preparation according to claim 1, characterized in that The weight composition of each component in every 1000ml is as follows:
4. The fat emulsion preparation according to claim 1, characterized in that The cyperus oleifera oil is refined and purified and meets the pharmaceutical standards, wherein the unsaturated fatty acid content is not less than 80%, the ratio of oleic acid to linoleic acid is (5-7):1, and the peroxide value is ≤1mmol·L -1 , methoxyaniline value ≤ 2mg·ml -1 , lysophosphatidylcholine ≤1.2mg / mL.
5. The fat emulsion preparation according to claim 1, characterized in that: The phosphatidylserine is one or more of soybean phosphatidylserine, sunflower seed phosphatidylserine, cotton seed phosphatidylserine, peanut seed phosphatidylserine, pine nut phosphatidylserine, egg yolk phosphatidylserine, and synthetic phosphatidylserine, or may be a mixed phospholipid of several different phosphatidylserines in any proportion.
6. The fat emulsion preparation according to claim 1, characterized in that The lecithin emulsifier is one or more of soybean lecithin, egg yolk lecithin, soybean lecithin, egg yolk lecithin, and synthetic lecithin, or a mixture of several different lecithins in any proportion.
7. The fat emulsion preparation according to claim 1, characterized in that The oleic acid emulsifier is oleic acid or sodium oleate.
8. The fat emulsion preparation according to claim 1, wherein the preparation comprises the following steps: 1) Prepare the materials according to the formula of injection or oral preparation in the claims; 2) Add cyperus oleiferus oil into a reaction kettle, heat it to an oil temperature of 30-70° C. under nitrogen protection, add vitamin AD, phosphatidylserine, lecithin emulsifier, and oleic acid emulsifier into the cyperus oleiferus oil, and completely dissolve the added substances under stirring; 3) Adding other water-soluble components to an appropriate amount of purified water to prepare an aqueous solution for later use; 4) Under nitrogen protection, slowly add the pre-prepared oil solution into the aqueous solution with stirring. If the particle size of phosphatidylserine cyperus oleifera oil emulsion needs to be controlled, a homogenizer, a micro jet pump and other equipment can be used for particle size control; 5) Add the remaining amount of water for injection to reach the specified capacity and stir; 6) filling and high temperature sterilization to obtain the phosphatidylserine fat emulsion preparation containing vitamin AD in cyperus oleifera oil. 7) The dosage is divided into 5-10 ml.
9. The fat emulsion preparation as claimed in claim 1, wherein the oral preparation can be an oral liquid, a lyophilized powder, a lyophilized powder capsule, a lyophilized powder granule, or a syrup.
10. The fat emulsion preparation according to claim 1, which is used for preventing and treating vitamin A and D deficiency. Such as rickets, osteomalacia, increased susceptibility to respiratory and digestive tract infections caused by subclinical vitamin A deficiency, night blindness, dry eyes, dry and keratinized skin, and senile bone. Children who need vitamin AD supplementation.
